Related Experiment Video
Updated: Aug 6, 2026

Biochemical Titration of Glycogen In vitro
Published on: November 24, 2013
Prenatal diagnosis of glycogen storage disease type IV
H Orhan Akman1, Charalampos Karadimas, Yolanda Gyftodimou
1Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Background:
Glycogen storage disease type IV (GSD-IV) is a rare autosomal recessive disorder due to mutations in the GBE1 gene causing deficiency of the glycogen branching enzyme (GBE). Prenatal diagnosis has occasionally been performed by the measurement of the GBE activity in cultured chorionic villi (CV) cells.
Methods:
Two unrelated probands with severe hypotonia at birth and death during the neonatal period were diagnosed with GSD-IV on the basis of postmortem histological findings. DNA analysis revealed truncating GBE1 mutations in both families.
Results:
Prenatal diagnosis was performed in subsequent pregnancies by determination of branching enzyme activity and DNA analysis of CV or cultured amniocytes. Detailed autopsies of the affected fetuses at 14 and 24 weeks of gestation demonstrated intracellular inclusions of abnormal glycogen characteristic of GSD-IV.
Conclusion:
Prenatal diagnosis of GSD-IV by DNA analysis is highly accurate in genetically confirmed cases.
Related Concept Videos
Inborn Errors of Metabolism
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Type I Diabetes III: Clinical Manifestations

